Precision Application of Clostridium Butyricm of Clinical Research on Osteoarthritis
Key facts
- Who runs it
- China Medical University Hospital
- Where
- Taiwan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 83 people enrolled
- Started
- 1 Apr 2023
- Ended
- 29 Feb 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Western Ontario and McMaster University Osteoarthritis Index (WOMAC)
- Visual Analogue Scale (VAS)
- Kellgren Lawrence Grading Scale (KL score)
- Quality of Life Questionnaires and Assessments:
- Record updated
- 26 August 2024
Who can take part
- Age
- 55 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- A. Patients aged 55 to 75 years old with degenerative arthritis, diagnosed by a physician as suitable for participation in this experiment
- Patients with early-stage degenerative arthritis symptoms, as interpreted by X-ray using the Kellgren Lawrence Grading Scale at grade 1 or 2, and determined by a physician to not require long-term treatment
- Patients with a high pain index when the knee is extended 40-70 mm
- Patients who feel knee pain, primarily those with a high Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index score (pain scale score >2.0 or total WOMAC scale score >12)
Who cannot take part
- Patients who have taken steroid medication for the treatment of degenerative arthritis
- A. Patients with a history of knee joint trauma or knee joint surgery (including arthroscopic surgery)
- Patients with severe cardiovascular, cerebrovascular, rheumatic, or psychiatric diseases
- Patients with infectious diseases or acute infections (e.g., fever, localized inflammation, abscess)
- Patients with systemic or metabolic diseases, or progressive bone degeneration caused by medication
- Cancer patients
- Patients with joint pain caused by other factors
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Osteoarthritis (OA) is a common joint disease worldwide. The main symptom is that the mechanical wear of the cartilage in the joint and leads to the abnormal proliferation of the surrounding bone and synovial tissue with the chronic inflammation and the narrowing of the joint cavity. The prevalence of OA is increasing due to population increasing and aging, and there are currently about 400 million OA patients in worldwide. The treatment methods of osteoarthritis are mainly divided into medicine and non-medicine therapy. The major function of medicine therapy is to reduce pain and the arthroscopic surgery (arthroscopy) is main treatment of non-medicine therapy. Thus, in this project the investigators will mainly focus on the precise application of Clostridium butyricum on OA and the investigators' previous study successfully demonstrated the therapeutic effects of Clostridium butyricum on OA animal model. Therefore, will test the clinical effects of OA patient with Clostridium butyricum treatment, and whether it is also possible to improve the symptom of OA patients.
The 2 groups in the trial
- Group A (placebo)Placebo, for comparison
Treatment: Western Ontario and McMaster University Osteoarthritis Index (WOMAC), Visual Analogue Scale (VAS), Kellgren Lawrence Grading Scale (KL score), and Quality of Life Questionnaires and Assessments:
- Group B (Treatment)Treatment being tested
Treatment: Western Ontario and McMaster University Osteoarthritis Index (WOMAC), Visual Analogue Scale (VAS), Kellgren Lawrence Grading Scale (KL score), and Quality of Life Questionnaires and Assessments:
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 26 August 2024